Why the study?
Antithrombotic therapy is not recommended for low-risk AF patients, but the impact of incident comorbidities and oral anticoagulation in initially low-risk patients was not well established.
Does oral anticoagulation therapy reduce ischemic stroke and composite outcomes in initially low-risk patients with nonvalvular atrial fibrillation who develop new stroke risk factors?
Does oral anticoagulation therapy reduce ischemic stroke and composite outcomes in initially low-risk patients with nonvalvular atrial fibrillation who develop new stroke risk factors?
In initially low-risk patients with nonvalvular atrial fibrillation, regular reassessment is crucial as approximately 30% develop new stroke risk factors within 2 years, and initiating oral anticoagulation in these patients significantly reduces ischemic stroke and composite adverse outcomes.
No takes yet. Share an insight, caveat, or question.
OAC use persists in guideline-defined low-risk AF; leaves open whether incident comorbidities warrant reclassification or therapy.
Choi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: